ArticleThe Kaohsiung journal of medical sciences2016
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori.
Article in The Kaohsiung journal of medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Comparative efficacy and safety of vonoprazan-based dual therapy vs. bismuth-based quadruple therapy forFrontiers in microbiology · 2026Pooled it
- Treatment ofWorld journal of gastroenterology · 2024Pooled it
- Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025Trial
- Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial.Scientific reports · 2025Trial
- Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.The Kaohsiung journal of medical sciences · 2017Trial
- Efficacy and safety of potassium-competitive acid blockers in eradicatingCaspian journal of internal medicine · 2026Review
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.Minerva gastroenterology · 2025Review
- Article
- Vonoprazan a novel potassium competitive acid blocker; another leap forward.Przeglad gastroenterologiczny · 2024Article
- Current research status and trends of potassium-competitive acid blockers in the treatment of acid-related diseases: a bibliometric analysis.Frontiers in pharmacology · 2024Article
- Review
- Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2023Article
- Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms ofGut and liver · 2021Review
- Genetic and Transcriptomic Variations for Amoxicillin Resistance inPathogens (Basel, Switzerland) · 2021Article
- Correlation Analysis ofIranian journal of public health · 2020Article
- The Potential Benefits of Vonoprazan asPharmaceuticals (Basel, Switzerland) · 2020Review
- Effect of Antibiotic Susceptibility andAntibiotics (Basel, Switzerland) · 2020Article
- Endoscopic severe mucosal atrophy indicates the presence of gastric cancer after Helicobacter pylori eradication -analysis based on the Kyoto classification.BMC gastroenterology · 2020Article
- Efficacy of Vonoprazan for Helicobacter pylori Eradication.Internal medicine (Tokyo, Japan) · 2020Review
- Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database.Digestion · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary eradication of H. pylori in routine clinical practice. Data for 573 patients who underwent primary H. pylori eradication therapy were retrospectively reviewed. Regimens included clarithromycin 200 mg, amoxicillin 750 mg, and an acid-suppressing drug [lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), esomeprazole 20 mg (EAC), or vonoprazan 20 mg (VAC)] twice daily for 1 week. Eradication was successful in 73% (419/573) of patients using intention-to-treat (ITT) analysis and 76% (419/549) of patients in per-protocol (PP) analysis. The VAC group had a significantly superior eradication rate compared with the LAC and RAC groups in ITT (VAC 83%, LAC 66% and RAC 67%, p < 0.01) and PP analysis (VAC 85%, LAC 69% and RAC 70%, p < 0.01), and had a similarly high eradication rate to the EAC group (83% in ITT and 87% in PP). Although the eradication rate in the VAC and EAC groups was not significantly higher than in the LAC and RAC groups in patients with mild gastric atrophy with both ITT and PP analyses, it was significantly higher in patients with severe gastric atrophy (p < 0.01). The VAC group had a significantly higher H. pylori eradication rate than the LAC and RAC groups, and a > 80% eradication rate regardless of the degree of atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.